Antithrombotic material and medical device

Patent metadata

Field	Value
Publication number	US-9415144-B2
Application number	US-201414186124-A
Country	US
Kind code	B2
Filing date	Feb 21, 2014
Priority date	Aug 22, 2011
Publication date	Aug 16, 2016
Grant date	Aug 16, 2016

Abstract

An antithrombotic material has an excellent anticoagulant activity and can form a stable coating layer on a base material through a simple and mild coating process. An antithrombotic material includes a copolymer configured to have 75% by mole to 25% by mole of a repeating unit (A) derived from diacetone(meth)acrylamide represented by the following formula (1) (wherein R 1 is a hydrogen atom or a methyl group) and 25% by mole to 75% by mole of a repeating unit (B) derived from a monomer having at least one sulfonate group selected from a group consisting of 2-(meth)acrylamide-2-methyl-propane sulfonic acid, vinyl sulfate, allyl sulfate, styrenesulfonic acid, sulfoethyl(meth)acrylate, and sulfopropyl(meth)acrylate in a molecule, or a salt of the monomer (the total amount of the repeating unit (A) and the repeating unit (B) is 100% by mole).

First claim

What is claimed is:

1. An antithrombotic material, comprising a copolymer consisting of 75% by mole to 25% by mole of a repeating unit (A) derived from diacetone (meth)acrylamide represented by the following formula (1):

wherein R 1 is a hydrogen atom or a methyl group, and 25% by mole to 75% by mole of a repeating unit (B) derived from a monomer having at least one sulfonate group selected from the group consisting of 2-(meth)acrylamide-2-methyl-propane sulfonic acid, vinyl sulfate, allyl sulfate, styrenesulfonic acid, sulfoethyl (meth)acrylate, and sulfopropyl (meth)acrylate in a molecule, or a salt of the monomer,
wherein the total amount of the repeating unit (A) and the repeating unit (B) is 100% by mole of the copolymer.

2. The antithrombotic material according to claim 1 , wherein the repeating unit (B) includes a repeating unit derived from 2-(meth)acrylamide-2-methyl-propane sulfonic acid or a salt thereof represented by the following formula (2):

wherein R 2 is a hydrogen atom or a methyl group.

3. The antithrombotic material according to claim 2 , wherein R 1 is a hydrogen atom in the formula (1), and R 2 is a hydrogen atom in the formula (2).

4. The antithrombotic material according to claim 1 , wherein a molar ratio of the repeating unit (A) to the repeating unit (B) is 30:70 to 70:30.

5. The antithrombotic material according to claim 1 , wherein a molar ratio of the repeating unit (A) to the repeating unit (B) is 30:70 to 50:50.

6. The antithrombotic material according to claim 1 , wherein a weight-average molecular weight of the copolymer is 10,000 to 10,000,000.

7. A medical device comprising a base material and a coating layer that coats the surface of the base material, wherein the coating layer includes the antithrombotic material according to claim 1 .

8. A medical device comprising a base material and a coating layer that coats the surface of the base material, wherein the coating layer includes the antithrombotic material according to claim 2 .

9. A medical device comprising a base material and a coating layer that coats the surface of the base material, wherein the coating layer includes the antithrombotic material according to claim 3 .

10. A medical device comprising a base material and a coating layer that coats the surface of the base material, wherein the coating layer is formed with a reaction product obtained by reacting the antithrombotic material according to claim 1 and a cross-linking agent.

11. A medical device comprising a base material and a coating layer that coats the surface of the base material, wherein the coating layer is formed with a reaction product obtained by reacting the antithrombotic material according to claim 2 and a cross-linking agent.

12. A medical device comprising a base material and a coating layer that coats the surface of the base material, wherein the coating layer is formed with a reaction product obtained by reacting the antithrombotic material according to claim 3 and a cross-linking agent.

13. The medical device according to claim 10 , wherein the cross-linking agent is a hydrazide compound having at least two hydrazide residues per molecule.

14. The medical device according to claim 11 , wherein the cross-linking agent is a hydrazide compound having at least two hydrazide residues per molecule.

15. The medical device according to claim 12 , wherein the cross-linking agent is a hydrazide compound having at least two hydrazide residues per molecule.

16. The medical device according to claim 7 , wherein the medical device is an implantable prosthesis, therapeutic device, an extracorporeal cyclic artificial organ, a catheter, or a guide wire.

17. The medical device according to claim 8 , wherein the medical device is an implantable prosthesis, therapeutic device, an extracorporeal cyclic artificial organ, a catheter, or a guide wire.

18. The medical device according to claim 9 , wherein the medical device is an implantable prosthesis, therapeutic device, an extracorporeal cyclic artificial organ, a catheter, or a guide wire.

Assignees

• Terumo Corp

Inventors

• Anzai Takao
• Hakamatani Tomoe

Classifications

• A61L27/34 Primary

  Macromolecular materials · CPC title

• C08L33/26

  Homopolymers or copolymers of acrylamide or methacrylamide · CPC title

• A61L33/064

  obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L33/062 takes precedence) · CPC title

• A61L33/068 Primary

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L33/062 takes precedence) · CPC title

• A61F2/04

  Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts (A61F2/18, A61F2/20 take precedence; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95) · CPC title